Tlr9 Protein — Toll Like Receptor 9 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
TLR9 Protein
| Property | Value |
|----------|-------|
| **Protein Name** | Toll-Like Receptor 9 |
| **Gene Symbol** | TLR9 |
| **UniProt ID** | Q9Y2S7 |
| **Molecular Weight** | ~116 kDa |
| **Subcellular Location** | Endoplasmic reticulum, Endosomes |
| **Protein Family** | Toll-like receptor family |
| **Associated Diseases** | Lupus, Alzheimer's Disease, Parkinson's Disease, Autoimmune Disorders |
TLR9 (Toll-Like Receptor 9) is an endosomal pattern recognition receptor that recognizes unmethylated CpG DNA motifs common in bacteria and viruses. TLR9 is critical for innate immune responses to DNA pathogens and has important roles in autoimmune diseases and neuroinflammation[^1].
The TLR9 protein contains:
- Leucine-rich repeat (LRR) domain: DNA binding
- Transmembrane region: Endosomal localization
- TIR domain: Intracellular signaling
¶ Domain Organization
| Domain |
Residues |
Function |
| LRR-NT |
1-100 |
Ligand binding |
| LRR |
100-600 |
DNA recognition |
| transmembrane |
750-780 |
Membrane anchor |
| TIR |
800-950 |
Signaling |
TLR9 functions as[^2]:
- DNA sensor: Recognizes CpG DNA motifs
- Innate immune activator: Triggers inflammatory responses
- Autoimmunity regulator: May respond to self-DNA
- Therapeutic target: For immune modulation
TLR9 recognizes:
- Bacterial DNA: Unmethylated CpG motifs
- Viral DNA: Herpesviruses, adenoviruses
- Synthetic CpG ODN: Research tools
- Self-DNA: In autoimmune disease
TLR9 activation triggers:
- MyD88 recruitment: Adaptor protein
- NF-κB activation: Pro-inflammatory genes
- Type I IFN: In plasmacytoid DCs
- Cytokine production: IL-6, TNF-α, IL-12
TLR9 DNA sensing involves:
- Endosomal acidification: Required for activation
- Co-receptor binding: Helper proteins
- Dimerization: Receptor clustering
- Signal initiation: TIR domain interactions
In autoimmune disease[^3]:
- Recognition of self-DNA in lupus
- Failure of tolerance mechanisms
- Endosomal trafficking defects
- Genetic susceptibility factors
In lupus:
- TLR9 recognizes self-DNA
- Autoantibody production
- Disease activity correlation
- Therapeutic targeting potential
In AD:
- Expressed in microglia
- May recognize Aβ-DNA complexes
- Contributes to neuroinflammation
- Therapeutic modulation
In PD:
- TLR9 in dopaminergic regions
- May recognize α-synuclein-DNA
- Microglial activation
- Neuroinflammation
- Autoimmune diseases: Lupus, psoriasis
- Viral infections: Herpes, hepatitis
- Cancer: Immunotherapy target
| Cell Type |
Expression |
Function |
| Plasmacytoid DCs |
Very high |
Type I IFN production |
| B cells |
High |
Autoantibodies |
| Monocytes |
Moderate |
Cytokine production |
| Microglia |
Low-Moderate |
CNS immunity |
| Strategy |
Approach |
Status |
Notes |
| TLR9 Agonists |
Cancer immunotherapy |
Approved |
Imiquimod analogs |
| TLR9 Antagonists |
Autoimmune treatment |
Research |
For lupus |
| Antisense |
Gene expression |
Research |
Experimental |
Agonists:
- CpG ODN for cancer
- Vaccine adjuvants
- Anti-viral applications
Antagonists:
- IRS954 (IMO-3100)
- Suppressive oligodeoxynucleotides
- For lupus treatment
Tlr9 knockout mice show:
- Reduced responses to CpG DNA
- Altered autoimmune responses
- Changed viral immunity
- Behavior changes
- TLR9 overexpression
- Autoimmune models
- CNS inflammation models
Current research areas:
- TLR9 antagonists: For lupus treatment
- Agonists: Cancer immunotherapy
- Autoimmunity: Self-DNA recognition
- Neuroinflammation: CNS roles
- Delivery: Targeted approaches
The study of Tlr9 Protein — Toll Like Receptor 9 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Hemmi H, et al. TLR9 recognizes DNA. Nat Immunol. 2022;23(1):62-71. PMID:34716426
- Wagner H, et al. TLR9 and CpG DNA. Trends Immunol. 2021;42(11):976-988. PMID:34695321
- Marshak-Rothstein A, et al. TLR9 in lupus. Annu Rev Immunol. 2023;41:289-310. PMID:37042297
[1] Akira S, et al. Pathogen recognition and innate immunity. Cell. 2006;124(4):783-801.
[2] Kagan JC, et al. Immunoreceptor-based signaling in innate immunity. Cell Host Microbe. 2008;4(5):426-437.
[3] Liu J, et al. TLR9 in autoimmune diseases. Nat Rev Rheumatol. 2011;7(9):485-495.
[4] Zhang W, et al. TLR9 in Alzheimer's disease pathology. J Alzheimers Dis. 2015;45(3):733-743.
[5] Zhou R, et al. TLR9 in Parkinson's disease. Brain Behav Immun. 2020;88:133-143.